Show document

A+ | A- | | SLO | ENG

Title: Survivin - an inhibitor of apoptosis and a new therapeutic target in cancer Authors: ID Pižem, Jože (Author) ID Cör, Andrej (Author) Files: PDF - Presentation file, download (185,35 KB) MD5: 2244DAB3FD8BB52EC4DAB9EF72DC6AA0   Language: English Typology: 1.04 - Professional Article Organization: OI - Institute of Oncology Abstract: Survivin is a unique member of the inhibitor of apoptosis (IAP) protein family. It inhibits apoptosis by interfering with post-mitochondrial events during apoptosis, thus blocking activation of caspases. The expression of survivin is among the most tumour specific of all human genes. It is overexpressed in most human cancers but is not detected in most normal tissues. Some molecular mechanisms of survivin upregulation in cancer have been elucidated, including loss of the wild-type p53. Tumours that overexpresssurvivin generally bear a worse prognosis and are associated with resistance to therapy. Its differential expression in caneer versus normal tissues makes survivin detection a useful tool in cancer diagnostics and a promising therapeutic target. Survivin targeting has resulted in increased spontaneous and induced apoptosis and inhibition of tumourgrowth. Some anticaneer drugs currently introduced into clinical practice might well act byinactivaring survivin. Publication status: Published Publication version: Version of Record Publication date: 01.01.2003 Publisher: Association of Radiology and Oncology Year of publishing: 2003 Number of pages: str. 195-202 Numbering: Letn. 37, št. 3 Source: Ljubljana PID: 20.500.12556/DiRROS-18110-149e7d9f-21bb-8a65-fda4-2effec6c5021  UDC: 616-006 ISSN on article: 1318-2099 COBISS.SI-ID: 17000409  Copyright: by Authors Note: BSDOCID101593; Publication date in DiRROS: 06.02.2024 Views: 162 Downloads: 33 Metadata:     Cite this work Plain text BibTeX EndNote XML EndNote/Refer RIS ABNT ACM Ref AMA APA Chicago 17th Author-Date Harvard IEEE ISO 690 MLA Vancouver : Copy citation

Share: Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:	Radiology and oncology
Shortened title:	Radiol. oncol.
Publisher:	Slovenian Medical Society - Section of Radiology, Croatian Medical Association - Croatian Society of Radiology
ISSN:	1318-2099
COBISS.SI-ID:	32649472

Secondary language

Language:	Slovenian
Title:	Zaviralec apoptoze survivin kot tarča ciljanega zdravljenja raka
Abstract:	Survivin sodi v družino beljakovin zaviralcev apoptoze (inhibitor of apoptosis, IAP). Zavira aktivacijo kaspaz, tako da vpliva na "po-mitohondrijske" dogodke med apoptozo. Survivin se (prekomerno) izraža v večini tumorjev, v normalnih tkivih pa ne. Poznani so nekateri molekularni mehanizmi, ki so odgovorni za prekomerno izražanje survivina v tumorjih, eden takih je izguba divjega tipa beljakovine p53. Tumorji, ki izražajo survivin, so v splošnem manj občutljivi na zdravljenje, preživetje bolnikov je slabše. Zaradi različnega izražanja survivina v tumorskem in netumorskem tkivu je survivin uporaben v molekularni diagnostiki tumorjev, hkrati pa primerna tarčaza razvoj takšnega načina zdravljenja, ki je usmerjeno proti tumorju in čim manj poškoduje normalna tkiva. Zaviranje delovanja survivina vodi v povečano spontano ali sproženo celično smrt (apoptozo), kar zavre rast tumorja. Nekatera novejša zdravila proti raku verjetno delujejo v veliki meri preko zaviranja delovanja survivina.

Back